UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Weekly ultra-hypofractionated radiotherapy in localised prostate cancer

Sundahl, Nora; Brand, Douglas; Parker, Chris; Dearnaley, David; Tree, Alison; Pathmanathan, Angela; Suh, Yae-eun; ... Murray, Julia; + view all (2024) Weekly ultra-hypofractionated radiotherapy in localised prostate cancer. Clinical and Translational Radiation Oncology , 47 , Article 100800. 10.1016/j.ctro.2024.100800. Green open access

[thumbnail of Brand_1-s2.0-S2405630824000776-main.pdf]
Preview
Text
Brand_1-s2.0-S2405630824000776-main.pdf

Download (708kB) | Preview

Abstract

Background: Moderately hypofractionated radiotherapy regimens or stereotactic body radiotherapy (SBRT) are standard of care for localised prostate cancer. However, some patients are unable or unwilling to travel daily to the radiotherapy department and do not have access to, or are not candidates for, SBRT. For many years, The Royal Marsden Hospital NHS Foundation Trust has offered a weekly ultra-hypofractionated radiotherapy regimen to the prostate (36 Gy in 6 weekly fractions) to patients unable/unwilling to travel daily. Methods: The current study is a retrospective analysis of all patients with non-metastatic localised prostate cancer receiving this treatment schedule from 2010 to 2015. Results: A total of 140 patients were included in the analysis, of whom 86 % presented with high risk disease, with 31 % having Gleason Grade Group 4 or 5 disease and 48 % T3 disease or higher. All patients received hormone treatment, and there was often a long interval between start of hormone treatment and start of radiotherapy (median of 11 months), with 34 % of all patients having progressed to non-metastatic castrate-resistant disease prior to start of radiotherapy. Median follow-up was 52 months. Median progression-free survival (PFS) and overall survival (OS) for the whole group was 70 months and 72 months, respectively. PFS and OS in patients with hormone-sensitive disease at time of radiotherapy was not reached and 75 months, respectively; and in patients with castrate-resistant disease at time of radiotherapy it was 20 months and 61 months, respectively. Conclusion: Our data shows that a weekly ultra-hypofractionated radiotherapy regimen for prostate cancer could be an option in those patients for whom daily treatment or SBRT is not an option.

Type: Article
Title: Weekly ultra-hypofractionated radiotherapy in localised prostate cancer
Location: Ireland
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ctro.2024.100800
Publisher version: http://dx.doi.org/10.1016/j.ctro.2024.100800
Language: English
Additional information: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, Radiology, Nuclear Medicine & Medical Imaging, Prostate cancer, Radiotherapy, Ultra-hypofractionation, ESTRO-SIOG GUIDELINES, ANDROGEN-DEPRIVATION, FREE SURVIVAL, OUTCOMES, THERAPY
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng
URI: https://discovery.ucl.ac.uk/id/eprint/10195054
Downloads since deposit
Loading...
35Downloads
Download activity - last month
Loading...
Download activity - last 12 months
Loading...
Downloads by country - last 12 months
Loading...

Archive Staff Only

View Item View Item